AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.


Date/time Interval

  • October 19, 2017 - October 18, 2022
  • Total Award Amount

  • 49200.00
  • Direct Costs

  • 37846.00
  • Sponsor Award Id

  • Contributor

  • Dumas, Jeanine   Investigator  
  • Galtarossa Xavier, Ana   Principal Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Wadhwa, Aman   Investigator  
  • Wolfson-Stockman M.D., Julie   Investigator